Alamar Biosciences’ mission is to transform the field of proteomics for early detection of cancer and other diseases. Following in the footsteps of genomics, proteomes will usher in a new era of precision health. The human plasma proteome, the complete set of proteins in human blood, has long been recognized as a gold mine of health and disease biomarkers. However, due to the low abundance and wide dynamic range of these proteins in the plasma, most of the plasma proteome has remained inaccessible with current technologies. We are creating the world’s most sensitive proteomics platform to unmask the deepest secrets of our proteome. Our fully automated, high throughput platform will empower new biomarker discoveries for early detection and prevention of common diseases.
Location: United States
Employees: 11-50
Total raised: $178M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Illumina V... | illuminaVe... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 12.01.2026 | - | $50M | T. Rowe Pr... |
| 27.02.2024 | Series C | $128M | - |
Mentions in press and media 20
| Date | Title | Description |
| 13.01.2026 | Alamar Biosciences Announces Launch of NULISAqpcr™ AD 5-plex Assay, Advancing Blood Based Biomarker Detection in Alzheimer's Disease Research | FREMONT, Calif., Jan. 13, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, is proud to announce the launch of its Research Use Only (... |
| 12.01.2026 | Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team | T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors FREMONT, Calif., ... |
| 10.10.2025 | Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer's Disease Research | New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable... |
| 29.07.2025 | Alamar Biosciences and the German Center for Neurodegenerative Diseases (DZNE) partner for Landmark Proteomic Profiling study in the Rhineland Study Cohort | NULISAseq™ CNS Disease Panel 120 and Inflammation Panel 250 to Power Biomarker Discovery in 23,000 Longitudinal Samples FREMONT, Calif., July 29, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the... |
| 28.07.2025 | Alamar Biosciences Showcases Pioneering Brain-Derived pTau Data at the Alzheimer's Association International Conference (AAIC) | Groundbreaking Insights into Neurodegenerative Disease Biomarkers to be Unveiled through 30+ Posters and Presentations at International Meeting FREMONT, Calif., July 28, 2025 /PRNewswire/ -- Alamar Biosciences, a company pioneering precisio... |
| 10.06.2025 | Alamar Biosciences, Alzheimer's Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer's Disease. | Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT, Calif., June 10, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of d... |
| 15.05.2025 | Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays | First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision prot... |
| 24.03.2025 | Alamar Biosciences Announces the Launch of the NULISAseq Mouse Panel 120 | Providing the largest and most comprehensive, high sensitivity, protein biomarker analysis to advance pre-clinical research FREMONT, Calif., March 24, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enabl... |
| 21.03.2025 | Revolutionizing Alzheimer's Research: The Power of Biomarkers and Global Collaboration | In the realm of Alzheimer's disease (AD) and related dementias, the quest for early detection and effective treatment is akin to navigating a labyrinth. Researchers are now armed with a new map: a multiplexed biomarker approach that promise... |
| 20.03.2025 | Benchmarking of a Multi-biomarker Low-volume Panel for Alzheimer's Disease and Related Dementia Research, Upcoming Webinar Hosted by Xtalks | www.alamarbio.com In this free webinar, discover a multiplexed biomarker approach for Alzheimer's and related dementias. Attendees will learn about a multiplexed assay for high-sensitivity, low-volume biomarker detection. The featured speak... |
Show more